$SEER

Seer to Report Second Quarter 2026 Financial Results on August 11, 2026

Seer, Inc. (Nasdaq: SEER) said it will release its second-quarter 2026 financial results on Aug. 11, 2026. The company will host a webcast conference call starting 1:30 p.m. PT / 4:30 p.m. ET, with audio available on its investor website and a replay afterward.

Original reporting
Published Aug 3, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 2:25 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Seer to Report Second Quarter 2026 Financial Results on August 11, 2026 — source image
Decision brief

The 30-second read

$SEERNeutralMed
01

Why it matters

The main tradable element is the calendar catalyst for earnings, which can affect options pricing, liquidity, and short-term positioning ahead of the print.

02

Market read

Event timing matters for volatility and hedging, but the article provides no new performance data.

03

What to watch

Implied volatility may be driven more by consensus expectations and any prior quarter’s trajectory than by the mere existence of an Aug. 11 call date.

Relevance 5/10Novelty 6/10Timing: earnings event scheduled for Aug. 11, 2026

Background

Seer is a proteomics company (Proteograph Product Suite) and this release is a standard investor-relations scheduling update.

Company-level read

Ticker impact

$SEERNeutralMedium confidence
Context

Seer announced it will report Q2 2026 financial results on Aug. 11, 2026, with a webcast starting 1:30 p.m. PT.

Expected impact

Likely modest pre-earnings positioning and volatility into Aug. 11; direction depends on the upcoming results and guidance.

Evidence & confidence

The article contains no Q2 numbers or guidance, only the reporting date and webcast timing, which primarily affects timing and event-driven trading rather than fundamentals immediately.

Market effects

Limited sector read-through because the release is only a reporting-date announcement, not results or guidance.

No specific regional spillover indicated beyond event-driven trading in the US small-cap biotech/proteomics space.

No global macro or cross-border transaction details provided.

Counterpoint

Because the disclosure lacks any new financial metrics or guidance, traders may treat it as routine and focus on other catalysts rather than pre-positioning aggressively.

Key entities

  • Seer, Inc.

    Nasdaq-listed proteomics company disclosing its Q2 2026 results date and webcast time.

Related articles

$SEERMedAI 8/10

Seer Inc. Q2 2026 Earnings: Revenue Misses $3.1 Million

Seer Inc. (Nasdaq: SEER) reported Q2 2026 revenue of $3.1 million, below consensus of $4.0 million, and a net loss of $0.31 per share versus a $0.22 loss expected. The company reaffirmed full-year 2026 revenue guidance of $16 million to $18 million. Shares fell about 2.78% after hours to $2.10.

$SEERMedAI 8/10

Seer, Inc. (SEER): Results of Operations and Financial Condition

Seer, Inc. (SEER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook REDWOOD CITY, Calif. – August 11, 2026 – Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial r

$SEERMedAI 8/10

Two Revised, Non-Binding Proposals Seek to Acquire All of Seer's Class A Shares

Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D. Rhea-AI Summary Seer (Nasdaq: SEER) confirmed receipt of two further revised, unsolicited, non-binding acquisition proposals for all outstanding shares of its Class A common stock. On July 28, 2026, the Radoff-JEC Group offered $2.55 per share in cash plus a contingent value right.

$LUCYMedAI 8/10

Top Biotech Gainers: LUCY Shines, SEER Gets Takeover Offer, OFIX, ENOV Rally On CMS Update

Biotech gainers: Innovative Eyewear (LUCY) rose 63% after preliminary Q2 2026 net sales of ~$0.99M (+71% YoY) and new retail orders; Seer (SEER) jumped 35% on an unsolicited $2.45/share cash takeover proposal plus contingent value rights; Orthofix (OFIX) and Enovis (ENOV) gained 16%/15% after CMS withdrew reimbursement changes for non-invasive bone growth stimulators.